
Government-backed hospital purchases of medical devices in China fell about 12 per cent year on year in the first five months of 2026, partly weighed down by “a new anti-corruption probe into hospitals”, dragging on the revenue of major Chinese medical device makers in the first half, said Linda Shu, head of China healthcare research at HSBC, in a report on July 10.
Among the latest Chinese companies joining the European push was heart medical device maker Jenscare Scientific, headquartered in Ningbo, eastern Zhejiang province, according to a filing with the Hong Kong stock exchange on July 8.
Its LuX-Valve Plus, the second device of its kind worldwide to win approval, has received CE certification under the European Union’s updated Medical Device Regulation, clearing it for sale across the region. The device replaces a damaged tricuspid valve, one of four valves in the human heart, through a vein rather than open-chest surgery.
The firm called the approval a “milestone” in its international strategy.

Don't Miss:
-
Chinese wife sparks outrage after beating mother-in-law for dating instead of babysitting
-
UAE says Iranian missiles struck tankers in Hormuz, killing and injuring crew
-
AI homework tools cut exam scores by 20%, study of 26,000 Chinese students finds
-
Is Japan a ‘spy paradise’ fuelling Russia’s war machine?
-
Dollar risks rising but Plaza Accord-style coordination not feasible now: ex-IMF adviser

A Jolting Autopsy on Malaysia’s Recent Elections
ASEAN Rehabilitates Myanmar’s Revamped Military Regime
Thailand in Parade of SEA Cyberscam Nations